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INTRODUCTION 
 Inflammatory bowel disease is one of the chronic debilitating 
illnesses and is a challenge to the treating gastroenterologist and to the 
patient. The most common form of inflammatory bowel disease in India 
is ulcerative colitis1.During 1960’s all the cases of chronic bloody 
diarrheas were diagnosed as amebic colitis or infective colitis. Tandon 
and chuttani et al first described ulcerative colitis in india2. There are lots 
of articles published from south India also cites its increasing  
incidence 3-5. 
 The incidence of ulcerative colitis varies from 1.2 to 20 per 
100,000 person-years and its prevalence from 40 to 246 per  100,000 
persons in studies conducted across the world 6. 
 Ulcerative colitis begins in rectal mucosa circumferentially and 
spreads to involve the proximal portions continuously without any skip 
areas. The inflammation involves mucosa and submucosa and no 
transmural involvement which is a feature of crohns disease. There are 
lots of diseases that can mimic ulcerative colitis from the commonly 
occurring infections to  the rare forms of atypical colitis. 
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 There is no single test to diagnose ulcerative colitis available now.  
The diagnosis of ulcerative colitis is based on a combination of clinical, 
endoscopic and histopathological findings. We have to rule out some 
infections and atypical colitis before making a diagnosis of ulcerative 
colitis. But still there is lots of confusion regarding the ultimate 
confirmation of the diagnosis before starting the therapy. Sometimes 
colonoscopy is not tolerated by the patients especially in acute setup. We 
need newer tools to make diagnosis. 
 Inflammatory bowel diseases (IBD) are subdivided into ulcerative 
colitis (UC) and Crohn’s disease (CD). Several lines of evidence suggest 
that CD and UC are different diseases. However, some patients (10–12%) 
cannot be easily classified into either and a final diagnosis of 
indeterminate colitis is made. Making an earlier, more accurate diagnosis 
of IBD is important as the management of CD and UC is different, 
especially when surgery is planned7,8. 
 A search for serological tests to differentiate CD from UC has been 
underway for a long time7. An ideal serological marker should have high 
sensitivity, high specificity, and high predictive values,9,10. 
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 So in this study I want to assess the usefulness of serological 
markers as a diagnostic test and correlation with other parameters in the 
natural history of ulcerative colitis and there are already lots of studies 
available regarding this in western literature but lacking in south India 
especially using panel of markers.  
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REVIEW OF LITERATURE 
 Inflammatory bowel disease is a chronic inflammatory disease of 
predominantly small and large intestine. Crohn’s disease and ulcerative 
colitis are the two main types. There are other less common entities like 
atypical microscopic colitis, primary Collagenous colitis and lymphocytic 
colitis. Although in many ways similar the diversion colitis, bypass 
enteropathy, radiation colitis and drug induced colitis have various 
identifiable etiologies14.  
 Ulcerative colitis is first described by Dr.Samuel Wilks in 1859 
and he described this as Idiopathic colitis and thought this disease is 
different from bacillary dysentery15. Tandon and chuttani et al first 
described ulcerative colitis in India 2 . 
     Epidemiology:        
  The most common form of inflammatory bowel disease in India is 
ulcerative colitis1. The incidence of ulcerative colitis varies from 1.2 to 20 
per 100,000   person-years and its prevalence from 40 to 246 per 100,000 
persons in studies conducted across the world 6 
 This disease is said to be more common in northern part of the 
world. Ulcerative colitis is more common in Jews population. But it may 
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present in all age groups with peak in second or third decade. Patients as 
young as 5 years can be affected. It is very rare beyond 8th decade. There 
is no predilection for any sex and male: female ratio is said to be 1:116. 
 More common in industrialized areas. Urban population, high 
socioeconomic status, immigrants to high risk areas are the other 
associations which are well documented17,18.         
Etiopathogenesis: 
 The disease is said to be due to the complex interplay of genetic, 
environmental, immunological and psycho logical factors. But the exact 
etiology is not known. 
 Evidence for genetic factors are best demonstrated in twins studies. 
Also there are lots of case reports in which parent son or siblings 
involved are reported. Another point is younger age of onset in familial 
form19 .There are more than one gene involvement and following genes 
are more commonly reported.MDR1 gene,HLA-DR2, DR1 and 
sometimes DR3 also20,21. 
 Environmental also involved in the pathogenesis as the studies 
conducted in immigrants. Infections are strongly suspected especially 
mycobacterium24. Involvement of intestinal micro flora also is postulated. 
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Cigarette smoking is another strong negative predictor22. Patients who 
quits smoking, mild smoker than heavy smoker, passive than active are at 
higher risk. 
 Dietary factors responsible are wheat, maize, cow’s milk, OC pills, 
refined sugar, alcohol, fruits, vegetables, toothpaste and breastfeeding, 
but none has been proved. Appendicectomy is a negative risk factor 22,23. 
 Immune mechanisms are also postulated. Both humoral and cell 
mediated immunity plays a role. Both the systems were deregulated 25,26. 
The best described autoantibody is pANCA. This autoantibody is present 
in 60 to 85% of ulcerative colitis patients. Most found evidence is in 
favor of its role as a susceptibility marker in first degree relatives of 
patients with ulcerative colitis. Regarding the cellular immunity both T 
cell mediated and nonspecific immunity also is implicated27,28. 
 Psychogenic factors also are postulated but later found to be 
associations due to the disease rather than cause of it29.  
Pathology: 
 Ulcerative colitis is a disease that starts from rectum and 
progressing proximally. It always involves the mucosa circumferentially. 
It involves mucosa and submucosa but not transmurally into serosa. 
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Continuous and symmetrical involvement is the hallmark of the disease. 
But there are some exceptions to this rule as in those treated with enemas 
will have rectal sparing. 75% of patients with left sided colitis have 
appendiceal involvement30.  
Endoscopy :              
Common sites of involvement  
                         rectosigmoid -45% 
                         left sided       - 35% 
                         pancolitis      - 20%      
 This is as per western data and this correlates with Indian data5,6. 
Macroscopic appearance:  
 Mucosa is hyperemic, edematous and granular in mild cases. In 
severe cases hemorrhagic mucosa with punctuate ulcers. The ulcers 
enlarge and extends into submucosa. They are irregular with overhanging 
edges. linear ulcers along the line of the taenia coli is also occurs. Due to 
recurrent attacks and subsequent regeneration of the mucosa, 
pseudopolyp formation occurs. In long standing cases the mucosa is 
atrophic and futureless resulting in shortening and narrowing of the 
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intestine occurs. Finally with severe disease the colon dilated and the 
mucosa becomes thinner and grossly ulcerated. Sometimes perforates 
with fibrinopurulent exudation 31. 
Microscopic  appearance: 
       During active disease 
1) lamina propria edema 
2) congestion of capillaries and venule 
3) Extravasation of RBC’s 
4) acute inflammatory cell infiltration 
5) cryptitis and crypt abscess 
6) goblet cell mucin depletion 
During healing phase 
1) inflammatory cells clears 
2) epithelial regeneration 
3) Regenerating epithelia mimics dysplastic cells. 
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During chronic phase 
 1) Distortion of crypts 
      2) Branching bifid glands 
      3) Paneth cell metaplasia 
      4) Crypt atrophy 
      5) <6 crypts per 1mm 32 
CLINICAL FEATURES: 
Rectal bleeding  
         Proctitis- fresh blood streaked on stool mistaken for hemorrhoids 
         Left sided UC- blood mixed with stool 
         Severe UC - Anchovy sauce stool (pus, blood & mucus) 
      Absence of rectal bleed rules out active UC 
Diarrhea 
           In 70% patients 
           30 % may have constipation 
            Tenesmus,  
  Nocturnal diarrhea 
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Abdominal pain : 
            Rare symptom 
            Vague pain usually 
Miscellaneous : 
           Fever  
           Edema, weight loss 
           Fatigue 
           Anorexia and vomiting. 
Signs:  
         Abdomen tender 
         Velvety mucosa in rectum 
         Fever, 
         Tachycardia, 
         Weight loss, 
         Clubbing, 
         Edema, 
         Hypoalbuminemia       
Extraintestinal manifestations:  
 Extraintestinal manifestations can affect any organ system, but they 
most commonly involve the skin, eyes, mouth, joints, and liver. These 
complications often are classified by their relations to the activity of the 
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colitis, but they can occur before, during, or following exacerbations of 
bowel disease33,34. 
Cutaneous/Oral 
 Angular stomatitis 
  Aphthous stomatitis 
Erythema nodosum 
Oral ulcerations 
Psoriasis 
Pyoderma gangrenosum 
Pyostomatitis vegetans 
Sweet's syndrome (acute febrile Neutrophilic dermatosis) 
Ophthalmologic 
     Conjunctivitis 
     Episcleritis 
     Retinal vascular disease 
      Scleritis 
     Uveitis, iritis 
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Musculoskeletal 
     Ankylosing spondylitis 
      Osteomalacia 
 Osteonecrosis 
          Osteopenia 
               Osteoporosis 
                Peripheral arthropathy 
                 Sacroiliitis 
     Hepatobiliary  
  Autoimmune hepatitis 
  Cholangiocarcinoma 
  Pericholangitis 
  Primary sclerosing cholangitis 
  Hepatic steatosis 
     Hematological 
  Anemia of chronic disease 
  Autoimmune hemolytic anemia 
  Iron deficiency anemia 
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  Hypercoagulable state 
  Leukocytosis or thrombocytosis 
  Leucopenia or thrombocytopenia 
CUTANEOUS/ORAL  
 The most common dermatologic manifestations of UC are 
complications of drug treatment. These include hypersensitivity, 
photosensitivity, and urticarial rashes related to sulfasalazine and less 
commonly to mesalamine. Patients receiving glucocorticoids often 
develop acne, which can be distressing cosmetically. Other common 
dermatologic manifestations associated with UC are erythema nodosum 
and pyoderma gangrenosum.  
 At least 10% of patients with UC develop oral aphthous ulcers. 
These lesions usually occur with flares of colitis and resolve on control of 
the bowel disease. Angular stomatitis and a sore tongue may be seen in 
patients with deficiencies of iron, B vitamins, or other micronutrients . A 
rare oral lesion that may be seen in patients with UC is pyostomatitis 
(pyoderma) vegetans, which appears as a pustular eruption of the oral 
mucosa resulting in a cobblestone appearance. 
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OPHTHALMOLOGIC  
 The two most common ocular manifestations associated with UC 
are episcleritis and uveitis, occurring in 5% to 8% of patients. Episcleritis 
is characterized by painless hyperemia of the sclera and conjunctiva 
without loss of vision. It typically parallels the activity of bowel disease 
and usually responds to anti-inflammatory therapy. 
Peripheral Arthropathy  
 Peripheral arthropathy occurs in 5% to 20% of patients with UC. 
The risk of arthropathy increases with the extent of colonic disease. 
Peripheral arthropathy can be classified into two distinct types36. 
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Peripheral Arthropathy Associated with Ulcerative Colitis 
FEATURE TYPE1 (PAUCIARTICULAR) 
TYPE2 
(POLYARTICULAR) 
Characteristics 
Frequency 35% 24% 
Duration of 
attacks <10 wk (median, 5 wk) 
Months to years (median, 
3 yr) 
Association 
with bowel 
disease activity 
Parallel Independent 
Joints Affected 
Number <5 ≥5 
Type Mainly large joints Mainly small joints 
Prevalence 
Knee > ankle > wrist > 
elbow > MCP > hip > 
shoulder 
MCP > knee > PIP > wrist 
> ankle > elbow > shoulder
          
     Hepatobiliary 
 The most important hepatobiliary complication associated with UC 
is PSC, which occurs in approximately 3% of patients (see Chapter 68). 
PSC is a chronic inflammatory disease of the biliary tree resulting in 
fibrosis and, eventually, cirrhosis and hepatic failure. Intrahepatic or 
extrahepatic ducts (or both) may be involved.  
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Miscellaneous: 
 Secondary systemic amyloidosis is a rare but serious complication 
associated with UC. Amyloidosis in these patients usually affects the 
kidney and manifests with proteinuria followed by the nephrotic 
syndrome and subsequent renal insufficiency. Diagnosis is made with a 
fat pad aspiration or alternatively, biopsies from the liver, rectum, or 
kidney. Pericarditis, pleuropericarditis, and constrictive pericarditis have 
been reported in patients with UC .This complication also may be related 
to mesalamine therapy. The pathogenesis of these complications is 
unknown, and their true association with UC is uncertain. Patients with 
UC can also develop abnormalities in pulmonary function, including an 
increase in functional reserve capacity and a decrease in diffusion 
capacity. Other pulmonary diseases that have been described in patients 
with UC include bronchiectasis, bronchiolitis, fibrosing alveolitis, 
pulmonary fibrosis, and pulmonary vasculitis. 
Diagnosis: 
 There is no single test that allows the diagnosis of UC with 
acceptable sensitivity and specificity. Diagnosis relies on a combination 
of compatible clinical features, endoscopic appearances, and histologic 
findings. The diagnosis of UC should be questioned if there is only a 
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single episode of acute illness or if the histopathology findings are 
nonspecific and lack signs of chronicity35. 
Endoscopy: 
 In patients presenting with their first attack of UC, sigmoidoscopy 
with biopsies usually is sufficient to confirm the diagnosis, thereby 
allowing initiation of therapy. In patients with active flares, 
sigmoidoscopy is best performed in unprepared bowel so the earliest 
signs of UC can be detected. Multiple biopsy specimens should be taken 
from throughout the colon to map the histologic extent of disease and to 
confirm the diagnosis36. 
 The hallmark of UC is symmetrical and continuous inflammation 
that begins in the rectum and extends proximally without interruption for 
the entire extent of disease. The earliest endoscopic sign of UC is a 
decrease or loss of the normal vascular pattern, with mucosal erythema 
and edema. As disease progresses, the mucosa becomes granular and 
friable. With more-severe inflammation, the mucosa may be covered by 
yellow-brown mucopurulent exudates associated with mucosal 
ulcerations.Mucosal ulcerations occur in areas of inflammation, vary in 
size from a few millimeters to several centimeters, and may be punctate, 
annular, linear, or serpiginous. Finally, severe UC is associated with 
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mucosa that bleeds spontaneously, and, with diffuse colitis, there may be 
extensive areas of denuded mucosa from severe mucosal ulcerations. 
Marked edema can at times lead to narrowing of the lumen. 
 In patients with long-standing UC, pseudopolyps may be present. 
Inflammatory pseudopolyps develop in active disease and result from 
inflamed, regenerating epithelium that is interposed among 
ulcerations,may give the colonic mucosa a cobble stoned appearance.  
Endoscopically, pseudopolyps typically are small, soft, pale, fleshy, and 
glistening;36   
 There is a loss of normal colonic architecture with long-standing 
inflammation that is characterized by muscular hypertrophy, loss of the 
normal haustral fold pattern, decreased luminal diameter, and shortening 
of the colon; a resultant featureless appearance of the colon in chronic UC 
gives rise to the lead pipe appearance seen on barium enema. Strictures 
can occur. Malignancy must be excluded in patients with long strictures 
without associated inflammation and strictures proximal to the splenic 
flexure. 
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     RADIOLOGY: 
 In the presence of severe disease, the luminal margin of the 
colon—the interface between the colonic mucosa and the luminal gas—
becomes edematous and irregular. Thickening of the colonic wall often is 
apparent on a plain film. The presence of marked colonic dilatation 
suggests fulminant colitis or toxic megacolon. A plain abdominal film 
also can detect unsuspected free air37. 
 The earliest radiologic change of UC seen on barium studies is fine 
mucosal granularity. The mucosal line becomes irregular and is not as 
sharp as that of a normal colon. With increasing severity, the mucosal line 
becomes thickened and irregular, and superficial ulcers are well shown en 
face. Deep ulceration can appear as collar-stud or collar-button ulcers in 
tangent, which indicates that the ulceration has extended through the 
mucosa to the muscularis propria.  
 Inflammatory and noninflammatory diseases of the colon can 
mimic UC and need to be considered in establishing the correct diagnosis. 
This differential diagnosis can be grouped broadly into three categories: 
Crohn's disease, infections, and noninfectious causes. 
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Serological markers in IBD: 
 Perinuclear antineutrophil  cytoplasmic autoantibodies (pANCA) 
are a well recognised marker for ulcerative colitis38. Antibodies to 
oligomannosidic epitopes of the yeast Saccharomyces cerevisiae (ASCA) 
are a marker associated  with Crohn’s disease 39. 
 The combination of a positive pANCA test and a negative ASCA 
testyielded a sensitivity, specificity, and positivepredictive value of 57%, 
97%, and 92.5% respectively for ulcerative colitis40.  
 The combination of a positive ASCA test and a negative pANCA 
test yielded a sensitivity, specificity, and positive predictive value of 
49%, 97%, and 96% respectively for Crohn’s disease41-43.   
 A search for serological tests to differentiate CD from UC has been 
underway for a long time. An ideal serological marker should have high 
sensitivity, high specificity, and high predictive values44. 
 The prevalence of pANCA varies from 40% to 80% in UC and 
from 0% to 20% in CD45. Testing for the presence of anti-S cerevisiae 
mannan antibodies (designated ASCA) was 64% sensitive and 77% 
specific for discriminating CD from UC and 89% specific for 
distinguishing CD from controls. 
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Differential Diagnosis of Ulcerative Colitis: 
Microscopic colitis 
Ischemic colitis 
Infectious colitis 
Amebic colitis 
Pseudomembranous colitis 
 
Endoscopic Differentiation of Ulcerative Colitis and Crohn's Disease 
FEATURE ULCERATIVE COLITIS CROHN'S DISEASE 
Distribution 
Diffuse inflammation that 
extends proximally from the 
anorectal junction 
Rectal sparing, frequent 
skip lesions 
Inflammation 
Diffuse erythema, early loss 
of vascular markings with 
mucosal granularity or 
friability 
Focal and asymmetrical, 
cobblestoning; granularity 
and friability less 
commonly 
Ulceration 
Small ulcers in a diffusely 
inflamed mucosa; deep, 
ragged ulcers in severe 
disease 
Aphthoid ulcers, linear or 
serpiginous ulceration; 
intervening mucosa is often 
normal 
Colonic 
lumen 
Often narrowed in long-
standing chronic disease; 
tubular colon; strictures are 
rare 
Strictures are common 
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ASSESSMENT OF DISEASE ACTIVITY  
 Assessment of disease activity is important for prognostication and 
therapeutic decision making. Although none of these indices is accepted 
universally as standard, one of the most commonly used is that of 
Truelove and Witts. This purely clinical classification categorizes disease 
as mild, moderate, or severe based on a combination of clinical findings 
and laboratory parameters, including frequency of bowel movements, 
rectal bleeding, fever, tachycardia, anemia, and elevated ESR. The 
Truelove and Witts classification is reliable and simple to use in clinical 
practice, although it is most applicable for patients with extensive colitis 
and might not adequately reflect disease severity in patients with limited 
colitis.          
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Truelove and Witts Classification46 
 
Mild 
<4 stools/day, without or with only small amounts of blood 
No fever 
No tachycardia 
Mild anemia 
ESR < 30 mm/hr 
Severe 
>6 stools/day, with blood 
Fever > 37.5?C 
Heart rate > 90 beats/min 
Anemia with hemoglobin level < 75% of normal 
ESR > 30 mm/hr 
 A numerical disease activity instrument that is more useful for 
patients with limited disease and for conducting clinical trials is the 
Ulcerative Colitis Disease Activity Index (UCDAI, also known as the 
Sutherland Index). his index, which combines clinical and endoscopic 
assessments, is the sum of scores from four components: stool frequency, 
rectal bleeding, sigmoidoscopic findings, and physician's global 
assessment. This disease activity index ranges from 0 to 12, with the 
higher total scores representing more-severe disease. In general, a patient 
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is considered to be in remission if the UCDAI score is 2 or less and to 
have severe disease if the score is greater than 10. Clinical response 
generally is accepted to be reflected by a decrease of three points from 
the patient's initial baseline score. An index very similar to the UCDAI 
that has been used extensively in recent randomized, controlled trials 
(RCTs) is the Mayo score, which incorporates the same four components 
as the UCDAI. 
 Other scales also have been developed, many of which are 
modifications of the Truelove and Witts classification and the UCDAI. 
None of these disease activity instruments has ever been formally 
validated. There also exist many endoscopic and histologic scales for 
grading the severity of colitis . Endoscopic findings do not always 
correlate with clinical symptoms, and such correlations generally are 
more consistent within individuals. Thus, although therapeutic decisions 
are based primarily on clinical status, it may be useful to follow the 
sigmoidoscopic mucosal appearance over time in an individual patient, if 
the clinical response to treatment is uncertain.  
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Endoscopic Assessment of Disease Activity in Ulcerative Colitis 
Endoscopic Assessment 
Grade 0 Normal mucosa 
Grade 1  Loss of vascular pattern 
Grade 2  Granular, nonfriable mucosa 
Grade 3  Friability on rubbing 
Grade 4  Spontaneous bleeding, ulceration 
 In addition to the typical categorization of disease activity into 
mild, moderate, and severe, an important subgroup is fulminant colitis. 
Patients with severe colitis who appear toxic, with fever higher than 38.3 
C (101 F), tachycardia, abdominal distention, signs of localized or 
generalized peritonitis, and leukocytosis, are considered to have 
Fulminant colitis. Toxic mega colon is said to occur when there is 
radiologic evidence of transverse colon dilatation to greater than 6 cm in 
an acutely ill patient. Fulminant colitis and toxic megacolon are clinical 
diagnoses, and complete colonoscopy examination should be avoided in 
patients with severe or Fulminant colitis because of the risk of inducing 
mega colon or perforation. In this patient population, a limited flexible 
Sigmoidoscopy is appropriate to ensure that the etiology of the symptoms 
is UC itself and not other conditions47,48. 
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TREATMENT  
MEDICAL  
The goals of therapy of UC are 
   To induce remission, 
           To maintain remission,  
           To maintain adequate nutrition,  
           To minimize disease- and treatment-related complications.                   
Aminosalicylates  
Oral  
 Sulfasalazine consists of an antibacterial component, sulfapyridine, 
bonded by an azo bond to a salicylate, 5-aminosalicylic acid (5-ASA, 
mesalamine) ( The drug was synthesized by Nana Svartz in 1938-1939 
and its benefit for the treatment of IBD was discovered serendipitously in 
1941-1942 by her when patients with UC receiving this medication for a 
presumed diagnosis of rheumatoid arthritis noted improvement in colitis 
symptoms . 5-ASA is the principal therapeutic moiety of sulfasalazine in 
IBD and that the sulfapyridine component of the parent drug serves as an 
inactive carrier, largely preventing absorption of 5-ASA in the small 
intestine and allowing it to be released in the colon49. Approximately 90% 
of sulfasalazine reaches the colon, and only a small amount is absorbed in 
the small intestine. On reaching the colon, the enzyme azoreductase, 
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which is elaborated by colonic bacteria, cleaves the azo bond to release 
the active constituent moiety, 5-ASA. After 5-ASA is absorbed from the 
colon, 20% of the compound undergoes hepatic acetylation, forming N-
acetyl 5-ASA, and is excreted in the urine. Sulfasalazine is one of several 
agents in the class of 5-ASA compounds that is considered to be the first 
line of therapy for inducing remission in patients with mild to moderate 
UC. Mesalamine derivatives have not been evaluated in a randomized, 
controlled fashion in patients with severely active disease. At a dose of 3 
to 6 g/day, sulfasalazine induces remission in 39% to 62% of patients 
with mild to moderate UC50,51. 
 Various formulations and controlled-release systems have been 
developed to deliver 5-ASA to specific sites of the gastrointestinal tract 
without the sulfapyridine moiety, which is thought to be responsible for 
most of the side effects. Olsalazine  is a 5-ASA dimer linked by an azo 
bond and is formulated in gelatin capsules. Balsalazide  consists of a 5-
ASA monomer linked to a biologically inactive carrier molecule, 4-
aminobenzoyl-β-alanine. Similar to sulfasalazine, 5-ASA is released from 
olsalazine and balsalazide in the colon upon cleavage of the azo bond via 
the bacterial enzyme azoreductase. Approximately 99% of the drug is 
delivered intact to the colon, and its metabolites are cleared rapidly in the 
urine52.  
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Oral 5-Aminosalicylic Acid Preparations and Sites of Delivery in the 
Gastrointestinal Tract 
DRUG FORMULATION SITE OF DELIVERY 
Prodrugs 
Sulfasalazine Sulfapyridine + 5-ASA Colon 
Olsalazine 5-ASA dimer Colon 
Balsalazide 4-aminobenzoyl β-alanine + 5-ASA Colon 
Mesalamine Preparations 
Asacol, 
Claversal, 
Salofalk 
pH sensitive, resin-coated; delayed 
release 
Distal ileum, 
colon 
Rowasa Enema Distal colon 
Canasa Suppository Rectum 
Pentasa Ethylcellulose-coated microgranules; controlled release 
Duodenum to 
colon 
Lialda 
pH sensitive, multi-matrix and 
polymethacrylate coated; delayed and 
slow release 
Distal ileum, 
colon 
 
 Three commonly used mesalamine preparations allow delivery of 
5-ASA before the drug reaches the colon: Pentasa, Asacol, and Lialda. 
Pentasa uses ethyl cellulose-coated microgranules that release 
mesalamine from the duodenum throughout the small bowel and the 
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colon; about 50% of 5-ASA is released in the small intestine, and the 
remainder is released in the colon. Asacol is a Eudragit-S-100–coated 
mesalamine tablet that is released at a pH greater than 7, usually in the 
distal ileum and the colon. With Asacol, about 15% to 30% of 
mesalamine is released in the small intestine. Lialda (MMx mesalamine) 
is a novel mesalamine formulation that uses a multimatrix structure 
composed of an inner lipophilic matrix and an outer hydrophilic matrix. It 
is coated with a pH-dependent polymethacrylate film to allow the delayed 
release of mesalamine in the terminal ileum and colon at a pH greater 
than 7. This technology also allows mesalamine to be released slowly and 
in close proximity to the colonic mucosa.  
 More important than the specific 5-ASA preparation is the dose-
dependent response when 5-ASA is used as an induction therapy for 
active UC. For this indication, mesalamine is not effective at doses lower 
than 2 g daily, and there is an increased response at doses of 4 to 4.8 g 
daily. The ASCEND I and II trials showed that mesalamine at doses of 
2.4 and 4.8 g/day have similar efficacy for patients with mildly active 
disease, but the higher dose (4.8 g/day) was more efficacious in patients 
with moderately active disease. This dose of mesalamine is comparable to 
12 g/day of sulfasalazine, which is impractical in clinical practice because 
of the high probability of intolerance. No RCT has evaluated the use of 
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aminosalicylates for severely active UC, but these agents are generally 
thought not to be effective in severely active disease.  
Glucocorticoids  
Systemic  
 At doses equivalent to 40 to 60 mg/day of oral prednisone, 
glucocorticoids are effective first-line therapy for moderate or severe 
flares of UC.] The use of doses higher than 60 mg/day is associated with 
increased side effects without appreciable clinical benefit and thus should 
be avoided. The addition of sulfasalazine to corticosteroids in moderately 
to severely active UC does not offer any incremental benefit. Although no 
study has directly compared the efficacy of oral and parenteral 
glucocorticoids, the latter commonly are used in severe disease. No 
adequately designed controlled study has been performed to confirm the 
clinical impression that continuous infusion of parenteral glucocorticoids 
is superior to pulse therapy. 
Immunomodulators  
Azathioprine and 6-Mercaptopurine  
 Of the various immunomodulatory agents, the most widely used 
are azathioprine and 6-MP. These two agents are purine analogs that 
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interfere with nucleic acid metabolism and cell growth and exert 
cytotoxic effects on lymphoid cells. They are inactive prodrugs with 
subtle structural differences. Azathioprine is nonenzymatically converted 
to 6-MP, which is then metabolized through a series of enzymatic 
pathways to active and inactive metabolites . The two primary 
metabolites of 6-MP are 6-thioguanine nucleotides (6-TGNs) and  
6-methylmercaptopurine (6-MMP). The 6-TGN metabolites are thought 
be responsible for the immunomodulatory action of azathioprine and  
6-MP and their bone marrow suppression property, whereas 
hepatotoxicity is thought to be related to 6-MMP. One key enzyme 
involved in the biotransformation of 6-MP is thiopurine methyltransferase 
(TPMT), which converts 6-MP to its inactive metabolites, 6-MMP and 6-
methylmercaptopurine ribonucleotides53. 
Biological Therapy  
 Recent advances in our understanding of the pathogenesis of IBD 
have resulted in the development of therapies targeted at specific 
molecules or mediators involved in the inflammatory processes of these 
diseases. Most studies evaluating the efficacy of these agents have been 
performed in patients with Crohn's disease, and only limited data are 
available for patients with UC55.  
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Anti-Tumor Necrosis Factor Antibodies  
 TNF is a key proinflammatory cytokine that has been demonstrated 
to play a role in several disease states, including IBD. Elevated TNF 
concentrations have been found in inflamed intestine in patients with 
Crohn's disease and UC, and stool and mucosal concentrations of TNF in 
patients with IBD have been shown to correlate with clinical disease 
activity. Infliximab is a chimeric monoclonal antibody of IgG1 subclass 
directed against human TNF-α. It consists of 75% human and 25% 
murine components 55 . The efficacy of infliximab in Crohn's disease is 
well established, and it is approved by the FDA to treat Crohn's disease 
and UC. Infliximab is thought to operate in Crohn's disease via a 
multitude of mechanisms, including antagonizing the activity of TNF-α, 
initiating cytotoxicity on immune cells, and inducing T-cell apoptosis. 
 Results from two large, multicenter, randomized, double-blind, 
placebo-controlled trials (ACT 1 and 2) showed efficacy of infliximab 
therapy in UC. In these two similarly designed trials, 728 patients with 
moderately to severely active UC who failed conventional therapy with 
glucocorticoids alone or in combination with thiopurines (ACT 1) or 
glucocorticoids alone or in combination with thiopurines and 5-
aminosalicylates (ACT 2) were randomized to placebo, infliximab 
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5 mg/kg, or infliximab 10 mg/kg at weeks 0 and 2 and then every eight 
weeks through week 46 (ACT 1) or week 22 (ACT 2). With respect to 
clinical response at week 8, in ACT 1 69% and 61% of patients receiving 
infliximab at 5 and 10 mg/kg, respectively, had a clinical response, 
compared with 37% of patients receiving placebo (P < 0.001 for both 
comparisons). In ACT 2 at week 8, 64% and 69% of patients receiving 
infliximab at 5 mg/kg and 10 mg/kg, respectively, had a clinical response, 
compared with 29% of patients receiving placebo (P < 0.001 for both 
comparisons). With respect to clinical remission at week 8 in ACT 1, 
39% and 32% of patients receiving infliximab at 5 mg/kg and 10 mg/kg, 
respectively, attained remission, compared with 15% of patients receiving 
placebo (P < 0.003 for both comparisons). In ACT 2 at week 8, 34% and 
28% of patients receiving infliximab at 5 mg/kg and 10 mg/kg, 
respectively, attained remission, compared with 6% of patients receiving 
placebo (P < 0.001 for both comparisons). The results for clinical 
remission at week 30 (ACT 1 and 2) and week 54 (ACT 1) were very 
similar for all groups, with highly significant greater than two-fold higher 
remission rates for the infliximab-treated patients. The proportions of 
patients with a sustained clinical response or remission also were 
significantly higher in the infliximab groups. Treatment with infliximab 
also was shown to have steroid-sparing and mucosal healing properties55.  
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 These data have led to the approval of infliximab by the FDA for 
patients with moderately to severely active UC who have had an 
inadequate response to conventional therapy. Infliximab is now accepted 
as part of the standard treatment options in patients with UC. Two other 
anti-TNF agents, adalimumab and certolizumab pegol, have shown 
efficacy for the induction and maintenance of remission in Crohn's 
disease but have not yet been studied in patients with UC56.  
Anti-Adhesion Molecules  
 Several agents directed at blocking small adhesion molecules have 
been evaluated for the treatment of UC. These molecules are 
glycoproteins expressed on the surfaces of endothelial cells and 
lymphocytes. Adhesion molecules are important in cellular trafficking in 
IBD and other diseases, in which immune and inflammatory cells from 
the periphery are recruited into sites of inflammation. Among these, 
natalizumab is a humanized IgG4 monoclonal antibody against 
lymphocyte adhesion molecules, α4 integrins. A pilot study of 10 patients 
with active UC suggested clinical benefit with a single infusion of 
3 mg/kg of natalizumab.Natalizumab currently is approved for treating 
patients who have Crohn's disease and in whom anti-TNF therapy has 
failed; its use in UC is now undergoing evaluation57.  
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 Another anti-adhesion molecule agent is MLN-02 (formerly called 
LDP-02), a humanized IgG1 monoclonal antibody to α4β7 integrin. In a 
phase 2 study, two infusions of 0.5 mg/kg of MNL-02 administered 29 
days apart were found to be effective in achieving clinical remission and 
response at six weeks after the initial infusion in patients with moderately 
active UC. 
Others  
 Although historically considered more important in the 
inflammation of Crohn's disease, as it is produced by Th1 cells, IL-2 also 
has been implicated in UC inflammation (see earlier). Two agents 
designed to block the binding of IL-2 to its receptor have been examined 
for potential efficacy in UC. Daclizumab, a humanized monoclonal 
antibody against the IL-2 receptor (CD25), was suggested to be beneficial 
in patients with refractory UC in a small open-label pilot study. A 
potential clinical benefit also has been reported with basiliximab, a 
chimeric monoclonal antibody to the IL-2 receptor, in a small, 
uncontrolled study of patients with steroid-refractory UC. Along with the 
emphasis on T-cell–mediated immune response in the pathogenesis of 
UC, a humanized monoclonal antibody to CD3, visilizumab, has shown 
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promise in an open-label phase 1 study of 32 hospitalized patients with 
UC whose disease failed to respond to intravenous glucocorticoids 58. 
 Other biological therapies include agents targeted at tissue repair 
and restitution following mucosal injury. In this regard, epidermal growth 
factor (EGF) is a potent mitogenic peptide that stimulates cell 
proliferation in the gastrointestinal tract. A preliminary study showed that 
EGF enemas at a dose of 5 ?g daily for two weeks was effective in 
treating mild to moderate left-sided UC when administered along with 
oral mesalamine. In contrast, another potent stimulant of intestinal 
epithelial cells, repifermin (keratinocyte growth factor 2) was not found 
to be more effective than placebo when administered intravenously in 
patients with active UC in a phase 2 dose-ranging study. Further studies 
clearly are necessary to confirm some of these early promising 
findings59,60.  
Cytapheresis  
 Active UC is characterized by activation and infiltration of 
leukocytes in the colonic mucosa. Because leukocyte-derived 
inflammatory cytokines play an important role in initiating and 
perpetuating the inflammatory process, reduction of peripheral blood 
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levels of leukocytes has been proposed as a therapeutic option for treating 
UC. 
Surgery: 
Indications for Surgery in Patients with Ulcerative Colitis 
Colonic dysplasia or carcinoma 
Colonic hemorrhage, uncontrollable 
Colonic perforation 
Growth retardation 
Intolerable or unacceptable side effects of medical therapy 
Medically refractory disease 
Systemic complications that are recurrent or unmanageable  
Toxic megacolon 
Proctocolectomy with Ileal Pouch-Anal Anastomosis  
 Restorative proctocolectomy with IPAA currently is the operation 
of choice for most patients with UC who require elective colectomy. In 
this procedure, the entire colon and rectum are removed, the anal 
sphincters are preserved, and a pouch is constructed from approximately 
20 cm of the distal ileum . Bowel continuity is established by 
anastomosing this pouch with the anal canal. An IPAA usually is 
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performed as a two-stage operation, during the first stage of which a 
temporary diverting ileostomy is created to allow the ileal pouch to 
heal61. 
Complications: 
• Toxic megacolon 
• Strictures 
• Dysplasia and colorectal cancer 
• Pouchitis62 
Prognosis: 
 Despite the burden of a chronic illness, more than 90% of patients 
with UC are able to maintain capacity for work after 10 years of disease, 
and data suggest that the overall quality of life is not impaired 
significantly, including marital issues, physical activities, and social 
function. The disease can affect the quality of life to some degree during 
acute flares, however, and even during periods of remission, patients 
might remain anxious for fear of relapse and alter their lifestyle 
accordingly.  
 Despite the morbidity of UC, mortality associated with the disease 
has dropped dramatically since the late 1950s and 1960s. The mortality 
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rate for a severe attack of UC was approximately 35% before the 
introduction of glucocorticoid therapy and now is less than 2%. Long-
term survival does not differ significantly from that expected for age-
matched controls, even with the risk of colorectal cancer that attends 
long-standing colitis. It is now generally believed that patients with UC 
have life expectancies comparable to those of the general population, 
although studies have reached conflicting conclusions. Mortality risk is 
greatest in the elderly and in those with extensive colitis, mostly related 
to postoperative complications within the first two years of disease and to 
comorbidities63.  
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AIM OF THE STUDY 
1.  To study the environmental and psychosocial factors associated 
with ulcerative colitis. 
2.  To study the clinical presentations, natural history and 
extraintestinal manifestations of ulcerative colitis. 
3.  To study the usefulness of panel of serological markers in the 
diagnosis of ulcerative colitis. 
4.  To study any correlation of serological markers with clinical 
presentation, disease severity and natural course of the disease. 
5.  To study the effects of therapy on serological markers and any 
correlation with poor response to therapy. 
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MATERIALS AND METHODS 
 This is a prospective study conducted in Department of digestive  
health and diseases, Government peripheral hospital, Annanagar, 
Chennai-102 from April 2009 to March 2011. The following inclusion 
and exclusion criteria were followed. 
Inclusion criteria: 
 Patients with clinical endoscopic, histological features suggestive 
of   Ulcerative colitis.  
Exclusion criteria: 
      1.  Patients with nonspecific colitis 
      2.   Patients with infective colitis 
      3.  Patients with radiation colitis 
      4.  Patients with diversion colitis 
      5.  Patients with features of ulcerative colitis but biopsy 
   indeterminate. 
 First the study protocol was designed and our institutional ethical 
committee approved the design of the study. Then the patients included in 
the study were explained about the entire study and informed consent was 
obtained.   
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 All the patients who attended our OPD during the study period 
with symptoms  of chronic diarrhea were included in our study. Those 
patients were informed about the colonoscopy procedure and consent 
obtained for colonoscopy.  
 All the patients prepared with PEGLEC preparation  as per routine 
protocol of our hospital. We usually instruct the patients to be on liquid 
diet 24 hours prior to  colonoscopy. One packet of PEGLEC mixed with 2 
liters of plain water and the patient were asked to drink it in the previous 
day evening. Two tablets of bisacodyl also were prescribed for patients 
with hard stools in the previous day night. Patient were not allowed 
anything by mouth from 10 pm onwards. Patients were given intravenous 
fluid if required.  
 Colonoscopy was done either with IV sedation or without any 
anesthesia in the morning. Colonoscopy was done by using PENTAX 
videocolonoscope. Biopsies were taken as required and sent to our 
pathologist for tissue diagnosis.            
 Diagnosis of Ulcerative colitis was made by combination of 
clinical features, endoscopic appearance and histopathological 
examinations.. They are investigated completely to diagnose ulcerative 
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colitis. Only histopathologically confirmed cases from our hospital during 
the study period were included in this study. 
 All the particulars of the patients were obtained as per proforma 
attached herewith it. Patients were interviewed about their demographic 
details first. Then detailed history about clinical presentation, natural 
history, past, personal, family histories, environmental and psychological 
factors prior to the onset of the disease were asked. Also extraintestinal 
manifestations were notified.  
 Complete hemogram, basic blood chemistry, liver function tests 
and other routine investigations were done as per proforma.   For 
serological markers 3 ml of blood taken separately and all the serological 
markers as mentioned in the proforma  were done by indirect 
immunoflourescent assay. Serological markers done are 
      1. Antibody to goblet cells-IgA and G 
      2. p ANCA IgA and G 
      3 c ANCA IgA and G 
      4 Antibody to pancreatic antigen  IgA and G 
      5 Antibody to pancreatic acini  IgA and G 
      6. ANA  
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ANCA INDIRECT IMMUNOFLUORESCENCE ASSAY 
 Determination of pANCA was performed by an indirect 
immunofluorescence technique on  ethanol fixed leucocytes according to 
the  International guidelines on ANCA. Fluorescein isothiocyanate 
conjugated rabbit antihuman IgG (specific for ã chains) (Dako, Glostrup, 
Denmark) was used. Patient sera were screened at a dilution of 1/20 in 
phosphate buffered saline. All slides were assessed by two well trained 
observers in a blinded fashion. 
ASCA ASSAY: 
 ASCA ELISA  Antigen consisted of phosphopeptidomannan 
(PPM) extracted from yeast cells from cultures in bioreactors. ELISA was 
performed as previously described. Briefly, plates were coated  with 100 
μl of PPM at a concentration of 1 μg/ml in sodium carbonate buffer  
(60 mM, Ph 9.6), for one hour at 37°C and overnight at 
 4°C, in moist chambers, and then washed four times in TNT (50 
mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.5). Patient sera 
were diluted 1/1000 in TNT and tested in duplicate. Alkaline phosphatase 
labelled goat antihuman immunoglobulin (IgG, IgA, IgM;H and L chains; 
Zymed, Biosoft, Paris, France) was diluted 1/3000 in TNT. A colour 
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reaction was obtained by using substrate Biotrol EIA 405 (Biotrol, Paris, 
France) for alkaline phosphatase.The plates were read at 405 nm on an 
Immunotech (Luminy, France) automatic reader. A coefficient of 
variation of less than  2% corresponded to repeatability of optical density 
values on a single microtitre plate. Interseries reproducibility of ASCA 
values showed a coefficient of variation of less than 5%. In a previous 
study it is described the standardisation procedure which was designed to 
avoid variations in individual values observed between series of the 
immunological assay. Each set of experiments involved six dilutions of 
the standard (1/500–1/32 000) from which a standard curve was derived. 
The highest absorbance (saturation) observed at 405 nm, was arbitrarily 
defined as 100% reactivity. Results of individual sera were expressed as a 
relative reactivity extrapolated from the standard  curve and calculated by 
the ELIOT  program (Immunotech, Luminy, France)..This was then used 
to determine the threshold of the test (3.12%). Serological markers were 
compared among various groups ie. pan colitis Vs limited colitis, new 
patients Vs treated patients, those with extraintestinal manifestations and 
those without  and also its usefulness as a diagnostic marker alone or in 
combinations.               
 First the usefulness of individual serological markers to diagnose 
disease was analyzed.   At  one side patients were separated into pan 
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colitis group and limited colitis group and various serological markers 
were analyzed. Then patients separated based on new cases and patients 
already on sulphasalazine   therapy and serological markers were 
analyzed. Both the above groups were demographically matched. Also 
patients were analyzed based on presence or absence of extraintestinal 
manifestations and its correlation with serological methods.          
Statistical methods:  
 When studying the relation between test results and clinical 
parameters, the chi square test or Fisher’s exact test was used when 
appropriate, and a multivariate analysis was performed using a logistic 
regression model. Significance was assigned to any probability value less 
than 0.05. 
 The statistical software package SPSS for windows version [SPSS 
Inc, Chicago III] was used to analyze the data. means and standard 
deviations were used to summarize data for continuous variables whereas 
percentages were used for categorical variables.        
Definition : Multiple extra intestinal involvement means > 2 systems 
involved 
Suphasalazine Response means patients on maintenance with 
sulphasalazine for > 2 years without increase in symptoms and or relapses 
controlled with sulphasalazine.  
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RESULTS 
 In this study period 11543 patients attended our OPD as new cases. 
Out of which 398 colonoscopies were performed during this period for 
varying indications .Out of which 120 cases chronic diarrhea cases were 
analysed. Among this 51 patients were having features suggestive of IBD 
endoscopically.11 patients were excluded  from final analysis. Among 
those excluded are 7 patients for having  not turned up for follow up and 
4 patients had inconclusive histopathological results.   Among this 40 
cases of histopathologically proven cases of ulcerative colitis were finally 
included in this study. 
Table : study particulars             
Serial 
Number : 
Factors Numbers 
1 Total OPD 11543 
2 Total colonoscopy 398 
3 Chronic diarrhea 120 
4 Endoscopically IBD 51 
5 Patients excluded 11 
6 Total included in study 40 
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 Among the 40 patients 20 patients were male and 20 patients were 
females.  From 15 years to70 years is the age range .Patients mean age in 
this study is 42.5 years. Peak onset is in the 3rd or 4th decade. All the 
patients were from low socioeconomic group and geographic region is 
around north Tamilnadu as it reflects the location of our hospital. 
Table 1. Demographic details: 
Factors Numbers 
Male/female 1:1 
Age range 15 to 70 years 
Mean age 42.5 years 
Commonest age group 3rd or 4th decade[19/40] 
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Table  2. Risk factors : 
S:no Risk factors present absent Cumulative 
% 
P value
1 Smoking 22 18 55 0.52 
2 Alcohol 6 34 15  
3 Tea 34 6 85 .00 
4 Unpasteurised 
milk 
28 12 70 .011 
5 Appendicectomy 0 40 -  
6 Breast feeding 36 4 90  
7 OC pills 0 20 -  
8 Chronic mental 
stress 
28 12 70 .011 
 
 All the known risk factors given in literature were analyzed using 
questionnaire. One patient had history of pulmonary tuberculosis. 
Majority were from urban areas and north Tamilnadu. Majority patients 
are Hindus by religion and poor socioeconomic status. But all these 
epidemiological data reflects are local factors.  
 None of the patients have family history of IBD. Ulcerative  colitis 
is more common among smokers in this study(55% vs 45%) but only 
15% of study population is consuming alcohol. Only  15% of the study 
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population is not breastfed. None of the patients underwent 
appendicectomy a mong the females none were using contraceptive pills. 
But 8o% of the study population used to drink lots of tea [p value .00] 
and 70 % of patients found to be using either unpasteurised milk or raw 
milk [p value 01]. most importantly 70 % of patients were suffered 
persistent mental agony long prior to the onset of IBD[P value .01]. 
 While analyzing the symptoms rectal bleeding and chronic 
diarrheas were more common and found in 90 %. of the patients. 
Abdominal pain is present in 70% of the patients. Fatigue and edema legs 
were found in 35%, 20% respectively. 31 of the patients were having 
chronic relapsing course[78% vs 22% ] and only 9 patients has chronic 
continuous course . 33 patients were showing good response to 
sulphasalazine[83%]. Sulphasalazine related adverse events were rare and 
found only in 4 patients [10%  p value .00]. 
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Table 3.  clinical features 
Serial 
no : 
symptom present absent Cumulative 
% 
P 
value 
1 Rectal bleed 36 4 90 .00 
2 Chronic 
diarrhea 
36 4 90 .00 
3 Abdominal 
pain 
28 12 70 .00 
4 fatigue 14 26 35 .58 
5 Edema legs 8 32 20 .00 
6 Chronic 
relapsing 
course 
31  77.5  
7 Chronic 
continuous 
course 
9  22.5  
8 Response to 
sulphasalazine 
33 7 82.5  
9 Sulphasalazine 
adverse events 
4 36 10 .00 
 
 The onset of the illness has no seasonal preference. The mean 
duration of symptoms before the diagnosis of the disease is 7 months.  
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Table 4. Extraintestinal manifestations 
Serial 
no 
System 
abnormalities 
present absent Cumulative% P 
value 
1 dermatologic 14 26 35 .58 
2 rheumatic 34 6  85 .00 
3 ophthalmologic 26 14 65 .58 
4 hepatobiliary 0 40 -  
5 pulmonary 12 28 30 .011 
 
 Extraintestinal manifestations are more commonly found  in this 
study. Dermatologic manifestations were found in 35% of the patients. 
Rheumatic manifestations are found in 85 % of the patient  
s. Ophthalmologic manifestations in 65%,and 30% patients had 
pulmonary manifestations. But characteristic hepatobiliary manifestations 
are not found in any of our patients. Pancreatic ,urologic and hematologic 
manifestations also are not found in the study population. But regarding 
extraintestinal manifestations patients need to be followed for longer 
period to know the true incidence. 
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Table 5. Prevalence of serological Markers  
Serial 
no: 
Serological marker positive negative Cumulative 
% 
1 Anti goblet cell 
antibody 
5 35 12.5 
2 P ANCA 27 13 67.5 
3 ASCA 4 36 10 
4 Anti pancreatic 
antigen antibody 
0 40 - 
5 ANA 15 25 37.5 
 
 Panel of serologic markers were done in the study population. Anti 
goblet cell antibodies were positive in 12.5%, p ANCA in 67.5%, ASCA 
in 10 % and ANA in 37.5%. antibody to pancreatic antibody is negative 
in all patients. 
  
  
54
Table 6. Disease extent    and serological markers  
S. 
No. 
Serolo-
gical 
marker 
Pancolitis 
Cumula
tive % 
P 
val-
ue 
Limited colitis 
%
Positive negative 
  Posi-
tive 
negative  
1 Anti 
goblet 
cell ab 
4 16 20 .15 1 19 5 
2 P ANCA 20 0 100 .00 7 13 35
3 ASCA 1 19 5 .29 3 17 15
4 Anti pan. 
antibody  
0 20   0 20  
5 ANA 10 10 50 .10 5 15 25
 
 In the cross analysis of patients with severe UC and serological 
markers, patients with pancolitis  are having 100 % positive for p 
ANCA[P<.OO] , 50% ANA,20 % antigoblet cell antibody and only 5% 
positivity for ASCA. At the same time patients with limited colitis has 
only 35 % positivity for p ANCA 
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Table 7. Serological markers in treatment naive patients  
S. 
No. 
Serological marker Treatmen
t naïve 
Posi
tive 
% 
P 
val
ue 
On 
treatment 
Posi
tive 
% 
pos neg pos neg 
1 Anti goblet cell 
antibody 3 17 
15 .63 2 18 10 
2 P ANCA 16 4 80 .09 11 9 67.5
3 ASCA 1 19 5 .29 3 17 15 
4 ANA 8 12 40 .74 7 13 37.5
 
 Then  we compared the two groups of treatment naïve and on 
treatment with panel of serological markers. There is a marked difference 
in p ANCA levels between treatment naïve and on treatment groups[80% 
vs 67.5  p value<.09] but this is statistically not significant. 
 When comparing the patients with more extraintestinal 
involvement with those of less involvement indicates value of p ANCA. 
The pANCA  is positive in those with severe extraintestinal involvement 
compared to other group[94 % vs 47% p value <.02].ANA also useful 
eventhough it is statistically not significant[60% vs 26 %  p <.08] 
.Antigoblet cell antibody has significant negative correlation with 
multiple extraintestinal involvement. 
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Table 8. Serological markers and  multiple  
extraintestinal  involvement 
S. 
No. 
Serological 
marker 
Severe  
involve-
ment 
Posit
ive 
% 
P 
value 
Mild  
involvement
Posi
tive 
% 
pos neg pos neg 
1 Anti goblet cell 
antibody 4 13 
23.5 .07 1 22 4.3 
2 P ANCA 16 1 94 .02 11 12 47.8
3  ASCA 1 16 5.9 .45 3 20 13 
5 ANA 9 8 60 .08 6 17 26 
 
Table 9. Serological markers and sulphasalazine response 
Serial 
no: 
Serological marker Good 
response 
Posi
tive 
% 
P 
valu
e 
Poor 
response 
Posi
tive 
% 
pos neg pos neg 
1 Anti goblet cell 
antibody 2 31 
6 .008 3  4 43 
2 P ANCA 20 13 61 .04 7 0 100 
3  ASCA 4 29 12 .33 0 7  
5 ANA 10 23 30 .04 5 2 33 
 
 Although p ANCA is found to be elevated  in both groups 
antigoblet cell antibody negativity predicts poor response to 
sulphasalazine[ p value <.008]   
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Table 10.  Serological  markers and natural course of UC 
Serial 
no: 
Serological 
marker 
Chronic 
relapsing 
Posi
tive 
% 
P 
val
ue 
Chronic 
continuous 
Posi
tive 
% 
pos neg pos neg 
1 Anti goblet cell 
antibody 5 26 
16 .19 0 9 0 
2 P ANCA 21 10 68 .95 6 3 66 
3  ASCA 3 28 10 .90 1 8 11 
4 ANA 10 21 32 .20 5 4 33 
 
 The role of serum markers in predicting the natural course  of 
illness is not well defined but antigoblet cell antibodies  is 100 % 
negative in patients who are going for a chronic continuous course. 
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DISCUSSION 
 Among the 40 patients 20 patients were male and 20 patients were 
females.  From 15 years to70 years is the age range .Patients mean age in 
this study is 42.5 years. Peak onset is in the 3rd or 4th decade as noted in 
the literature[Tandon et al]. All the patients were from low 
socioeconomic group, Hindus by religion, from urban areas and 
geographic region is around North Tamilnadu as it reflects the location of 
our hospital .this epidemiological features correlates with the available 
literature. 
 In the present study we analyzed the genetic, environmental and 
psychological factors in the study population. The significant findings 
noted are consumption of raw or unpasteurized milk in 70% [p value of 
0.011]. Then regular consumption of tea as the beverage is found in 85% 
[ p value of 0.00]. 
 The presence of chronic persistent mental stress is found in 70%[p 
value of 0.011] as noted in the literature. But the other risk factors such as 
lack of breastfeeding, use of OC pills are not significantly identified in 
our study. None of the study population had appendicectomy [Rutgeerts  
P, D’Haens]  and only one patient had pulmonary tuberculosis in the past. 
Contrary to literature the majority of the study population are smokers 
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[55%] either active or passive[D Jones et al]. No family history of UC 
was found in our study. 
 In the present study we analysed the clinical features and rectal 
bleeding and chronic diarrhea were the most common symptoms and is 
found in 90 % of the study population. Abdominal pain is present in 70% 
of the patients. Fatigue and edema legs were found in 35%, 20% 
respectively. And this clinical pattern correlates with available literature.  
 In this study 31 of the patients were having chronic relapsing 
course[78% vs 22% ] and only 9 patients has chronic continuous course . 
33 patients were showing good response to sulphasalazine[83%]. We 
found  Sulphasalazine as a cheaper drug and more useful. In  this study 
sulphasalazine related adverse events were rare and found only in 4 
patients [10%  p value .00]. the mean duration of symptoms before 
diagnosis was made is 7 months which is as reported in literature. 
 In this study  rheumatic manifestations are found in 85 % of the 
patients. Ophthalmologic manifestations in 65% but others are rare. one 
of our actually presented first with unrelenting arthritis  and started on 
NSAID ,then she subsequently started manifesting colonic symptoms. 
Surprisingly pulmonary symptoms were found in 30 % of the patients. 
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None of the hepatobiliary manifestations were found in this study which 
is contrary to the available literature[Thayumanavan et al].  
 In the present study, we assessed the prevalence of ASCA pANCA, 
anti goblet cell antibodies and ANA  in a small population of ulcerative 
colitis and their value in differentiating between pancolitis and limited 
colitis,  correlation with histopathology for diagnostic sensitivity and 
specificity, sulphasalazine response and no response,  presence or   
absence  of multiple extraintestinal manifestations and  prediction of 
natural course.  
 At present, it appears that ASCA and   pANCA are strongly 
associated with CD and UC, respectively. Our percentages of serum 
samples from patients with UC  which were pANCA positive[67.5%] and 
ASCA positive [10%]  are comparable to the data reported in 
literature[Ferrante M et al]. But antigoblet cell antibodies are positive in 
only [12.5%] patients. 
 In our study population of 20 patients with pancolitis all showed p 
ANCA positivity[p .00]. The presence of pANCA in UC was dependent 
of disease extent which is contrary to available literature. Although 
statistically not significant ASCA is more positive [15 %] in patients with 
limited colitis than pancolitis[5%]    
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 Increasing evidence supports the concept of clinical and genetic 
heterogeneity in IBD and serum immune markers have been used to 
characterize subgroups of patients. pANCA were also present in patients 
who had been  on treatment for longer periods confirming previous 
reports.  [Severine et al] . But p ANCA is found to be more positive in 
treatment naïve[80%] than on treatment group[67.5%] with a p value of 
0.09 [ Dubinsky MC et al].  
 In the present study, the presence of p ANCA could be associated 
with particular clinical features in the form of more extraintestinal 
manifestations [94% ,p value of 0.02] which is not supported by existing 
literature., thus confirming our previous report. However, to confirm 
whether ANCA represent a serological marker of a clinical severity we 
need further studies. 
 In the present study p ANCA was positive in [61%] sulphasalazine 
responders and when combine with antigoblet antibody negativity[94%] 
it significantly correlates with sulphasalazine response p=0.004.Behera 
et al described elevation of ANA in steroid dependant patients. However 
the serological markers does not predicts the natural course of the disease. 
But antigoblet cell antibodies were found to be  negative in all the 
patients who is running a chronic continuous course in this study.  
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 However, since variation in prevalence of serological markers, 
such as pANCA, have been observed worldwide, it is recommended that 
multicentre, prospective studies be conducted. 
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CONCLUSION 
 
1. Positive p ANCA along with negative ASCA can be used as an 
additional diagnostic marker in ulcerative colitis. 
2. Positive p ANCA along with negative ASCA is a marker of disease 
extent. 
3. Positive p ANCA along with negative antigoblet cell antibodies 
can predict poor response to drug therapy. 
4. Positive p ANCA can predict multiple  extraintestinal system 
involvement warrants longterm followup. 
5. Positive p ANCA along with negative  antigoblet cell antibodies 
can predict chronic continuous course of ulcerative colitis. 
6. Extraintestinal manifestations are common and rheumatologic 
manifestations were the most common of it. 
7. Psychological factors have a definitive precipitating role in 
ulcerative colitis. 
 
Normal Splenic Flexure
Colonoscopic view of normal 
splenic flexure with haustral folds 
and normal vascular pattern.
Normal Transverse Colon
This endoscopic image depicts colon 
showing haustral folds with normal 
vascular pattern.
Mild Ulcerative Colitis
Colonoscopic view showing patchy 
loss of vascular pattern friability 
and few erosions covered by white 
exudate. 
 
 
 
Ulcerative Colitis: Mayo Score 2
Colonoscopic view showing loss of 
vascular pattern friability and fine 
ulceration.
Ulcerative Colitis: Mayo Score 3
Colonoscopic view showing 
extensive ulcerations, friability and 
loss of vascular pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name :     Age :  Sex :   DD 
HD No. 
 
Residence :     Occupation :   
 Mobile No.: 
 
 
EPIDEMIOLOGICAL PAST HISTORY 
North / South   DM  
Ethnicity   SHT  
Religion   CAHD  
Urban / Rural   PTB  
Socio Economic Status   SD  
  BA  
FAMILY HISTORY  JAUNDICE  
  ABD-SURGERY  
  APPENDICECTOMY  
  ANY OTHER   
PERSONAL HISTORY DIET HISTORY 
Smoker  Rice : Boiled / Raw  
Heavy   Wheat / Maize  
Moderate  Milk - Type  
Mild  Sugar – Refined  
Ex.  Fruits or Vegetables  
Passive   OC Pills  
Alcohol Abuse  Toothpaste  
Tobacco   Breast Fed / or Not  
Betel nut / Betel Lime  Non Veg. Foods  
Carbonated Drinks  Any other   
CLINICAL EXTRA INTESTINAL  
On set to Diagnosis  Rheumatic A (+) or  (-)  
On set Stress  
 Seasons  
 H/o Swollen joint in the past / present  
H/o. Reduced Physical activity 
 
Rectal Bleeding   H/o Morning stiffness  
Diarrhea  H/o Low Back pain at rest / improve 
with activity  
 
Constipation  H/o Restricted spine / hand movement  
Abdominal Pain   O/E Clubbing  
Anorexia / Wt. Loss / 
Nausea / Vomiting  
 Joint swelling : Sym / Pauci / Poly / Mig.   
Fever  METABOLIC : A (+) OR (-)  
Fatigue  H/o Fractures, Hip, Back   
Peripheral Edema  H/o Generalized Bone Pain   
Other Symptoms   H/o Muscle weakness   
COURSE :  H/o Hypocalcemia   
.One attach only  O/E Waddling gait   
Fulminant  HBP A (+) OR (-)  
Chronic Continuous   H/o Jaundice  
Chronic Intermittent  H/o Cholangitis  
Any other   H/o RUQ Pain  
DERMATOLOGIC A (+) or (-) H/o Pancreatic Pain  
 
 
< 
Erythema Nodosum  UROLOGICAL A (+) OR (-)  
Pyoderma Gangrenosum  H/o Renal Colic   
Sweet Syndrome  PULMONARY  A (+) OR (-) 
Apthous ulcers  H/o Chronic Productive cough   
Any other   H/o Wheeze / Dyspnea / Hemoptysis   
  RS  
OPHTHALMOLOGIC A (+) OR (-) SULPHA SALAZINE USERS : 
H/o Painful eye  Anorexia / Nausea / Vomiting  
H/o Blurred vision  Head ache / Back ache  
H/o Photophobia  Alopecia  
H/o Irritation  H/o Colitis  
H/o Burning eye  H/o Chest pain  
O/E Miosis  H/o Cough / Wheeze / Dyspnea  
Abnormal Pupillary res.  H/o Jaundice  
Ciliary Flush  H/o Pancreatic Pain  
Tenderness Eye  H/o Fever  
Redness between vessels   H/o Arthralgia  
Hyperemic vessels  H/o Infertility  
Violet Eye  Any other   
Slit Lamp Examination  CIBD PROFILE  
ENDOSCOPY Ab to Goblet cells – IgA and IgG  
Rectosigmoid  PANCA IgA and IgA  
Leftsided  Ab to DNA bound Lactoferrin IgG  
Pancolitis  Ab to Pancreatic Antigen rPAg1 IgA/G   
Ileal Disease  Ab to Pancretic Antigen rPAg2 IgA/G  
Perianal Disease   Ab to Pancreatic Acini IgA and IgG  
Grading  ASCA IgA and IgG  
    
    
    
    
LABORATORY PARAMETERS : SERUM  
Stool – OVA / CYST  Calcium   
Urine – Albumin / Sugar  Phosphorus  
Deposits / RBC  Vitamin D  
BLOOD PTH  
Hb%  HOMOCYSTINE 
TC  CRP  
DC  LIPID PROFILE : TGL  
ESR  LDL / VLDL  
RBC count  HDL   
BT / CT  Total Cholesterol   
Platelet count  HBS Ag   
Peripheral Smear  Anti HCV Ab   
RBC Parameters  X-rays : Chest   
Blood Urea / Sugar / Cre  Others   
Serum Na + / K+ / Cl- / 
HCO3- 
   
LIVER FUNCTION TEST   
TB / DB  USG ABDOMEN 
OT  MRCP  
PT  ERCP  
SAP  CECT  
TP  DEXA  
ALB / GLO  ECG In all leads  
Serum Amylase  HPE 
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No Sex Severity /Old Int. Response Course Goblet ANCA ASCA Pan ANA
1 52/F 1 2 1 1 1 2 1 2 2 1
2 30/F 1 1 1 1 1 2 1 2 2 2
3 24/F 2 2 2 1 2 2 2 2 2 2
4 36/F 1 2 2 1 1 2 1 2 2 2
5 57/M 1 1 1 2 1 1 1 2 2 2
6 60/F 2 1 1 1 2 2 1 2 2 2
7 37/M 1 2 1 2 2 2 1 2 2 1
8 38/M 1 2 1 1 1 1 1 2 2 1
9 30/M 2 1 2 1 1 2 2 1 2 2
10 47/M 2 2 2 1 1 2 1 2 2 2
11 45/M 1 2 2 1 1 2 1 2 2 2
12 45/M 2 2 2 1 3 2 2 2 2 2
13 40/M 1 1 2 1 1 2 1 2 2 1
14 55/F 2 2 2 1 1 1 2 2 2 1
15 37/M 2 2 2 1 1 2 2 1 2 2
16 45/M 2 2 2 1 1 2 2 1 2 2
17 28/F 1 1 2 2 2 1 2 2 1
18 25/F 1 1 2 2 1 2 1 2 2 1
19 65/F 1 1 2 1 1 2 1 2 2 2
20 42/M 2 1 2 1 1 2 1 2 2 1
MASTER CHART - 1
No Sex Severity /Old Int. Response Course Goblet ANCA ASCA Pan ANA
21 62/F 1 1 1 2 1 1 1 2 2 1
22 24/F 2 1 2 1 1 2 2 2 2 2
23 54/M 2 1 2 1 1 2 2 2 2 2
24 40/F 1 1 1 2 1 1 1 2 2 2
25 53/M 1 1 1 1 1 2 1 2 2 2
26 70/M 2 1 1 1 1 2 1 2 2 1
27 32/F 1 2 1 1 1 2 1 2 2 2
28 24/M 1 1 1 1 1 2 1 2 2 1
29 50/M 2 1 1 1 1 2 1 2 2 2
30 37/F 2 1 2 1 1 2 2 2 2 2
31 54/F 2 1 1 1 1 2 1 2 2 1
32 56/M 2 2 2 1 1 2 2 2 2 2
33 46/M 2 2 2 1 1 2 2 2 2 2
34 38/M 1 1 2 1 1 2 1 2 2 2
35 48/M 1 2 1 2 2 2 1 2 2 1
36 35/M 2 2 2 1 1 2 1 2 2 2
37 65/F 2 2 1 1 2 2 2 2 2 1
38 22/F 2 2 2 1 1 2 2 2 2 2
39 45/F 1 2 1 1 2 2 1 1 2 2
40 15/F 1 2 2 1 2 2 1 2 2 1
S.No Age & Sex
On set to
Diagnosis Smoking Alcohol Tea
Un
Past.
Milk
Appendi
Cectomy
Breast
Feeding OC Pill
Chronic
Mental
Stress
Rectal
Bleeding
Chronic
Diarrhea
Abdomin
al
Pain Edema Fatigue Derm Rheu Opthal HPB Pul
1 52/F 7 Months 1 2 1 1 2 1 2 1 1 1 1 2 1 1 1 1 2 2
2 30/F 1 Month 2 2 2 1 2 1 2 1 2 2 1 2 1 1 2 1 2 2
3 24/F 2 Years 1 2 1 2 2 2 2 2 1 1 2 2 1 1 1 2 2 2
4 36/F 1 Month 2 2 1 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2
5 57/M 3 Months 1 1 1 2 2 1 2 1 1 1 1 2 1 1 1 1 2 2
6 60/F 3 Months 1 2 1 1 2 1 2 1 2 2 1 2 2 1 1 1 2 2
7 37/M 1 Year 1 2 1 1 2 1 2 2 1 1 2 2 2 1 1 2 2 2
8 38/M 2 Years 1 1 2 1 2 1 2 2 1 1 1 2 1 2 1 1 2 1
9 30/M 9 Months 2 1 1 2 2 1 2 2 1 1 1 2 1 1 1 1 2 1
10 47/M 4 Months 2 2 1 2 2 1 2 1 1 1 1 2 2 2 1 2 2 1
11 45/M 6 Months 1 2 1 1 2 1 2 1 1 1 1 2 2 2 2 1 2 1
12 45/M 8 Months 1 2 1 1 2 1 2 1 1 1 1 2 2 2 1 2 2 2
13 40/M 8 Months 1 2 1 1 2 1 2 1 1 1 1 2 1 2 1 1 2 1
14 55/F 9 Months 2 2 1 1 2 1 2 1 1 1 1 1 2 2 1 2 2 2
15 37/M 6 Months 2 2 1 2 2 1 2 1 1 1 2 1 2 2 1 1 2 1
16 45/M 9 Months 1 2 2 1 2 2 2 1 1 1 2 1 2 2 1 1 2 1
17 28/F 7 Months 2 2 1 2 2 1 2 1 1 1 2 1 2 2 1 1 2 2
18 25/F 8 Months 2 2 1 1 2 1 2 1 1 1 1 2 2 2 1 1 2 1
19 65/F 1 Month 1 2 1 1 2 1 2 2 1 1 1 2 2 2 1 1 2 2
20 42/M 1 Month 2 2 1 1 2 1 2 2 1 1 2 2 2 2 1 2 2 2
21 62/F 7 Months 1 2 1 1 2 1 2 1 1 1 1 2 1 1 1 1 2 2
MASTER CHART  - 2
S.No Age & Sex
On set to
Diagnosis Smoking Alcohol Tea
Un
Past.
Milk
Appendi
Cectomy
Breast
Feeding OC Pill
Chronic
Mental
Stress
Rectal
Bleeding
Chronic
Diarrhea
Abdomin
al
Pain Edema Fatigue Derm Rheu Opthal HPB Pul
22 24/F 1 Month 2 2 2 1 2 1 2 1 2 2 1 2 1 1 2 1 2 2
23 54/M 2 Years 1 2 1 2 2 2 2 2 1 1 2 2 1 1 1 2 2 2
24 40/F 1 Month 2 2 1 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2
25 53/M 3 Months 1 1 1 2 2 1 2 1 1 1 1 2 1 1 1 1 2 2
26 70/M 3 Months 1 2 1 1 2 1 2 1 2 2 1 2 2 1 1 1 2 2
27 32/F 1 Year 1 2 1 1 2 1 2 2 1 1 2 2 2 1 1 2 2 2
28 24/M 2 Years 1 1 2 1 2 1 2 2 1 1 1 2 1 2 1 1 2 2
29 50/M 9 Months 2 1 1 2 2 1 2 2 1 1 1 2 1 1 1 1 2 1
30 37/F 4 Months 2 2 1 2 2 1 2 1 1 1 1 2 2 2 1 2 2 1
31 54/F 6 Months 1 2 1 1 2 1 2 1 1 1 1 2 2 2 2 1 2 1
32 56/M 8 Months 1 2 1 1 2 1 2 1 1 1 1 2 2 2 1 2 2 1
33 46/M 8 Months 1 2 1 1 2 1 2 1 1 1 1 2 1 2 1 1 2 2
34 38/M 9 Months 2 2 1 1 2 1 2 1 1 1 1 1 2 2 1 2 2 2
35 48/M 6 Months 2 2 1 2 2 1 2 1 1 1 2 1 2 2 1 1 2 2
36 35/M 9 Months 1 2 2 1 2 2 2 1 1 1 2 1 2 2 1 1 2 2
37 65/F 7 Months 2 2 1 2 2 1 2 1 1 1 2 1 2 2 1 1 2 2
38 22/F 8 Months 2 2 1 1 2 1 2 1 1 1 1 2 2 2 1 1 2 2
39 45/F 1 Month 1 2 1 1 2 1 2 2 1 1 1 2 2 2 1 1 2 2
40 15/F 1 Month 2 2 1 1 2 1 2 2 1 1 2 2 2 2 1 2 2 2
